著者
Kana Takayama Kohei Fujii Hiroki Yamaguchi Yumika Miyoshi Yuhei Uehara Shimpei Nagata Yoshinari Obata Motohiro Kosugi Yoji Hazama Tetsuyuki Yasuda
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.60, no.6, pp.905-910, 2021-03-15 (Released:2021-03-15)
参考文献数
22
被引用文献数
1 2

Hypoglycemia should be avoided when treating patients with diabetes. Repaglinide is an insulin secretagogue with a low hypoglycemic risk because of its rapid- and short-acting effects. However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency. We herein report an elderly patient with type 2 diabetes mellitus and severe renal insufficiency who received repaglinide and hypoglycemia three days after starting clopidogrel. The concomitant use of repaglinide and clopidogrel can lead to hypoglycemia, especially in patients with severe renal insufficiency.

言及状況

外部データベース (DOI)

Twitter (6 users, 6 posts, 14 favorites)

I recently learned about this drug-drug interaction, which is why I wanted to share the question I had via a poll! https://t.co/lXi7RV5sT0
報告その3 https://t.co/raPm30ZkTd

収集済み URL リスト